STATIC is pragmatic, open-label, randomized, non-inferiority trial, in which CD patients in remission will be randomized to either continue aminosalicylate therapy or withdraw treatment. The primary objective of the trial is to determine whether withdrawal of aminosalicylates is non-inferior to continuation of aminosalicylates in Crohn’s disease (CD). The primary endpoint of the trial is highly clinically meaningful, namely occurrence of any CD‑related complication (surgery, hospitalization, or other complication) within 24 months after enrollment.
STATIC has been badged with the approval of the CIRC Network. CIRC was founded in late 2016 through close collaboration with Crohn’s and Colitis Canada. Our mission is to establish an infrastructure for collaborative research amongst a network of academic and community IBD practices throughout Canada.
For Canadian clinical researchers, the CIRC offers a platform through which multicenter research proposals can be considered. Following a formal review process, the CIRC works with the investigators of successful proposals to fully develop study protocols and secure funding. The CIRC has project managers dedicated to coordinating multicenter projects. As well as being part of the network, recruiting investigators will receive academic recognition for successful recruitment as outlined in the publication charter.